VYEPTI dosing and administration overview

VYEPTI dosing and administration step 1

Withdraw 1 mL from a single-dose vial of VYEPTI and inject into a 100 mL bag of 0.9% Sodium Chloride Injection, USP. No other diluents may be used.*

VYEPTI dosing and administration step 2

Use an IV set with a 0.2 μm or 0.22 μm in-line or add-on sterile filter. Always infuse at room temperature.

VYEPTI dosing and administration step 3

Infuse over approximately 30 minutes. After infusion is complete, flush the line with 20 mL of 0.9% Sodium Chloride Injection, USP.

*300 mg dose: To prepare the solution, withdraw 1 mL of VYEPTI from each of 3 single-dose vials using a sterile needle and syringe. Inject the resulting 3 mL content into a 100 mL bag of 0.9% Sodium Chloride Injection, USP.

Schedule appointments with your patients once every 3 months (12 weeks).

Dosing and administration details

Dosing

  • The recommended dosage is 100 mg administered by IV every 3 months
  • Some patients may benefit from a dosage of 300 mg administered by IV every 3 months

Administration

  • Do not administer VYEPTI as an IV push or bolus injection
  • No other medications should be administered through the infusion set or mixed with VYEPTI
  • VYEPTI single-dose vials contain no preservative; discard any unused portion remaining in the vial
  • VYEPTI is to be administered in a healthcare facility

Supplies

  • Sterile needle and syringe
  • 100 mL bag of 0.9% Sodium Chloride Injection, USP
  • IV set with a 0.2 μm or 0.22 μm in-line or add-on sterile filter
  • 20 mL of 0.9% Sodium Chloride Injection, USP, for flushing line

Dilution and storage

Dilution

  • VYEPTI requires dilution prior to administration. Dilute only in a 100 mL bag of 0.9% Sodium Chloride Injection, USP
  • Gently invert the VYEPTI solution to mix completely. Do not shake
  • Following dilution, VYEPTI solution must be infused within 8 hours
    • During this time, VYEPTI solution should be stored at room temperature, 20°C to 25°C (68°F to 77°F)

Storage

  • VYEPTI injection is a clear to slightly opalescent, colorless to brownish-yellow solution supplied as a carton containing one 100 mg/mL single-dose vial
    • Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use
    • Do not freeze

No loading dose is required for VYEPTI.

VYEPTI CONNECT Enrollment Form

Get your patients started with VYEPTI

Download and fill out the VYEPTI CONNECT Enrollment Form to initiate a benefits investigation on behalf of your patient.

Reference:
  1. VYEPTI [package insert]. Deerfield, IL: Lundbeck Seattle BioPharmaceuticals, Inc.
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.